RT Journal Article SR Electronic T1 Genetic SNUPN variants cause spinocerebellar atrophy by disrupting global splicing in Purkinje cells JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.07.11.24310169 DO 10.1101/2024.07.11.24310169 A1 Okubo, Mariko A1 Ogawa, Megumu A1 Eura, Nobuyuki A1 Inoue, Yukiko U. A1 Dewa, Ken-ichi A1 Owa, Tomohiro A1 Miyashita, Satoshi A1 Murakami, Terumi A1 Nakamura, Hisayoshi A1 Hayashi, Shinichiro A1 Nonaka, Ikuya A1 Ogata, Katsuhisa A1 Hoshino, Mikio A1 Inoue, Takayoshi A1 Nishino, Ichizo A1 Noguchi, Satoru YR 2024 UL http://medrxiv.org/content/early/2024/07/12/2024.07.11.24310169.abstract AB We identified genetic variants in the SNUPN gene, which encodes the adapter protein snurportin-1 for the nuclear import of U1 snRNPs, in two families affected by spinocerebellar ataxia. We have elucidated the pathogenicity of these variants and the molecular pathomechanisms underlying this disease by assessing mutant snurportin-1 properties in vitro, cerebella at the morphological and molecular levels ex vivo, and motor functions in Snupn-variant knocked-in mice in vivo. Mutant snurportin-1 impaired nuclear-cytosol shuttling, leading to defective nuclear transport of U1 snRNPs in cerebellar Purkinje cells. This resulted in aberrant splicing and expression of genes essential for Purkinje cell development and impaired dendrite formation. The malformation of Purkinje cell dendrites resulted in hypoplasia and premature migration of granule cell precursors and interneurons, leading to abnormal lobe development and atrophy in the cerebellum.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIntramural Research Grant for Neurological and Psychiatric Disorders of NCNP (3-9, 5-6, and 5-7 to SN, MH, TI and IN) and by AMED under Grant Numbers JP23bm1223001s0102, JP23ek0109617s0402 (IN), JP23ak0101195s0101 (SN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethic approval and consent to participate All clinical information and materials used in the present study were obtained for diagnostic purposes with written informed consent. The study was approved by the Ethics Committee of National Center of Neurology and Psychiatry (Approved No. A2019-123, A2019-124).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes